{
    "organizations": [],
    "uuid": "51cdb1cf5ed76d826187ef8eae1e8052cae3fd9b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glaxosmithkline-inc-says-trelegy-e/brief-glaxosmithkline-inc-says-trelegy-ellipta-approved-in-canada-idUSFWN1RI0P6",
    "ord_in_thread": 0,
    "title": "BRIEF-GlaxoSmithKline Inc Says Trelegy Ellipta Approved In Canada",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 5 (Reuters) - GlaxoSmithKline Inc:\n* TRELEGY ELLIPTA APPROVED IN CANADA AS FIRST INHALER FOR LONG-TERM, ONCE DAILY TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE\n* TRELEGY ELLIPTA AVAILABILITY IS EXPECTED JUNE 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-05T23:43:00.000+03:00",
    "crawled": "2018-04-06T21:49:44.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "glaxosmithkline",
        "inc",
        "trelegy",
        "ellipta",
        "approved",
        "canada",
        "first",
        "inhaler",
        "daily",
        "treatment",
        "chronic",
        "obstructive",
        "pulmonary",
        "disease",
        "trelegy",
        "ellipta",
        "availability",
        "expected",
        "june",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}